This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into Alnylam's recent topline vutrisiran data from the HELIOS-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM)

Ticker(s): ALNY

Who's the expert?

Institution: Stanford 

  • Cardiologist and Instructor at Stanford University School of Medicine.
  • Manages patients at the amyloid center at Stanford and directs the amyloid clinic at the Palo Alto VA.
  • Research focuses on Investigating the molecular mechanisms behind genetic risk factors for human cardiovascular disease focusing on amyloidosis, cardio-oncology, and atherosclerotic diseases.

Interview Questions
Q1.

Roughly how many patients do you treat with ATTR-CM?

Added By: sara_admin
Q2.

What are your thoughts on the recent data from the HELIOS-B Phase 3 study of vutrisiran?

Added By: sara_admin
Q3.

If you had to rate your level of excitement on a 1 to 10 scale for the potential of vutrisiran, what would it be and why?

Added By: sara_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.